Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy

被引：2
|
作者：
Zaidi, Neeha
Huff, Amanda
Marcisak-Davis, Emily
Haldar, Daniel
Heumann, Thatcher
Konig, Max
Mog, Brian
Montagne, Janelle
Longway, Gabriella
Andaloori, Lalitya
Lyman, Melissa
Danilova, Ludmila
Nauroth, Julie
Kagohara, Luciane
Fertig, Elana
Azad, Nilo
Jaffee, Elizabeth
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 22期
关键词：
D O I：
10.1158/1538-7445.PANCA22-IA013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA013
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Intercepting pancreatic cancer development with oncogene targeted immunotherapy
    Jaffee, Elizabeth M.
    CANCER PREVENTION RESEARCH, 2022, 15 (12)
  • [2] A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer.
    Haldar, Saurav Daniel
    Judkins, Carol
    Ferguson, Anna
    Abou Diwan, Elizabeth
    Lim, Su Jin
    Wang, Hao
    Nauroth, Julie
    Goggins, Michael
    Laheru, Dan
    Jaffee, Elizabeth M.
    Azad, Nilofer Saba
    Zaidi, Neeha
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS758 - TPS758
  • [3] T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer
    Melief, Cornelis J. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (22): : 2143 - 2144
  • [4] Enhanced anti-tumor activity through targeted immunotherapy combined with mutant KRAS inhibition in pancreatic cancer
    Creech, Amanda
    Lee, Hailey
    Rashid, Khalid
    Le, Thuc
    Premji, Alykhan
    Luu, Tony
    Kassem, Ahmad
    Zhao, Weihang
    Li, Luyi
    Wu, Nanping
    Pardi, Norbert
    Wohlschlegel, James
    Donahue, Timothy
    Radu, Caius
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [5] Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
    Rosner, S.
    Zaidi, N.
    Wang, H.
    Smith, K.
    Nauroth, J.
    Guo, M.
    Fitzpatrick, P.
    Riemer, J.
    Barnes, A.
    Wenga, P.
    Feliciano, J.
    Hann, C.
    Lam, V.
    Murray, J.
    Scott, S.
    Anagnostou, V.
    Levy, B.
    Forde, P.
    Brahmer, J.
    Jaffee, E.
    Marrone, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S382 - S383
  • [6] The elucidation of drug resistance mechanisms against KRAS-targeted therapy in pancreatic ductal adenocarcinoma
    Takeda, Mitsunobu
    Yao, Wantong
    Draetta, Giulio
    Mori, Ryouta
    Sekido, Yuki
    Hata, Tsuyoshi
    Hamabe, Atsushi
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Uemura, Mamoru
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2024, 115 : 168 - 168
  • [7] NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer
    Deng, Daiyong
    Begum, Habeebunnisa
    Liu, Tong
    Zhang, Jiangyan
    Zhang, Qiang
    Chu, Ting-yu
    Li, Hong
    Lemenze, Alexander
    Hoque, Mainul
    Soteropoulos, Patricia
    Hou, Pingping
    JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 221 (11):
  • [8] From bench to bedside: current development and emerging trend of KRAS-targeted therapy
    Chen, Yi
    Liu, Qiu-pei
    Xie, Hua
    Ding, Jian
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (04) : 686 - 703
  • [9] A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer.
    Haldar, Saurav Daniel
    Heumann, Thatcher Ross
    Berg, Maureen
    Ferguson, Anna
    Lim, Su Jin
    Wang, Hao
    Nauroth, Julie
    Laheru, Dan
    Jaffee, Elizabeth M.
    Azad, Nilofer Saba
    Zaidi, Neeha
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS814 - TPS814
  • [10] KRAS-targeted therapy in the treatment of non-small cell lung cancer
    Yun, Jina
    Nakagawa, Reid
    Tham, Kenneth
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 422 - 430
12345